Physician profile
Robert J Hernandez, JR.
NPI 1104998046
$2,561.17
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,142 · 2020: $557 · 2021: $763 · 2022: $55.70 · 2023: $43.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $43.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $43.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $513.66 | 2019-2020 | |
| Lilly USA, LLC | $317.94 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $270.81 | 2019-2021 | |
| Abbvie INC. | $243.40 | 2021 | |
| Pfizer INC. | $142.93 | 2019-2020 | |
| Clarus Therapeutics INC. | $133.72 | 2021 | |
| Genentech USA, INC. | $108.69 | 2019 | |
| Indivior INC. | $108.00 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $89.13 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $79.65 | 2019-2020 | |
| Antares Pharma, INC. | $79.52 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $63.90 | 2020 | |
| Optos, INC. | $59.63 | 2021-2023 | Panoramic Ophthalmoscope |
| Acadia Pharmaceuticals INC | $55.70 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $48.25 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $44.15 | 2019 | |
| Sunovion Pharmaceuticals INC. | $40.65 | 2020 | |
| Orexo US, INC. | $27.76 | 2019-2021 | |
| Upsher-Smith Laboratories LLC | $21.80 | 2019 | |
| Galderma Laboratories, L.P. | $19.10 | 2019 | |
| Novo Nordisk INC | $18.26 | 2021 | |
| Ironwood Pharmaceuticals, INC | $18.16 | 2020 | |
| Fidia Pharma USA INC. | $16.74 | 2021 | |
| Eisai INC. | $15.96 | 2020 | |
| Ironshore Pharmaceuticals INC. | $12.65 | 2019 | |
| Janssen Biotech, INC. | $11.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.